ALDH1 Bio-activates Nifuroxazide to Eradicate ALDH^High Melanoma-Initiating Cells

Area of Science:

• Oncology
• Pharmacology
• Biochemistry

Background:

• 5-Nitrofurans are antibiotic pro-drugs with potential anticancer activity.
• Cancer-initiating (stem) cells often express high levels of aldehyde dehydrogenase (ALDH) enzymes.
• Targeting these specific cancer cell subpopulations is a key challenge in cancer therapy.

Purpose of the Study:

• To investigate the bio-activation mechanism of 5-nitrofurans by ALDH enzymes.
• To determine the efficacy of nifuroxazide as a selective cancer therapeutic.
• To explore the combination of nifuroxazide with BRAF and MEK inhibitors in melanoma.

Main Methods:

• Enzyme assays to determine nifuroxazide selectivity for ALDH1 isoforms.
• Cell-based assays using melanoma cell models with varying ALDH1 expression.
• In vivo studies in patient-derived melanoma xenografts.
• Analysis of ALDH1 expression in patient melanomas treated with BRAF/MEK inhibitors.

Main Results:

• Nifuroxazide is selectively bio-activated by ALDH1A1/1A3, not ALDH2.
• This activation involves a two-hit mechanism: ALDH1 oxidation and conversion to cytotoxic metabolites.
• ALDH1-high melanoma cells are sensitive to nifuroxazide, while ALDH1A3 mutations confer resistance.
• Nifuroxazide targets and eliminates ALDH1-high melanoma-initiating cells.
• Combined therapy with BRAF/MEK inhibitors and nifuroxazide shows synergistic effects in preclinical models.

Conclusions:

• Nifuroxazide acts as a selective pro-drug targeting ALDH1-high cancer stem cells.
• This mechanism offers a novel therapeutic strategy distinct from ALDH1 inhibition.
• The combination of nifuroxazide with BRAF/MEK inhibitors presents a promising approach for melanoma treatment.